Squarepoint Ops LLC Sells 132,507 Shares of OptimizeRx Corp. $OPRX

Key Points

• Squarepoint Ops LLC reduced its OptimizeRx position by 74.6% in the second quarter, selling 132,507 shares and retaining 45,064 shares. Institutional investors collectively own 76.47% of OPRX.
• Analysts maintain a generally positive outlook, with six Buy ratings, two Holds and one Sell; the stock has a consensus rating of Moderate Buy and a $11.43 price target.
• OptimizeRx reported quarterly earnings of $0.16 per share, exceeding the $0.11 consensus estimate, while revenue of $20.5 million also topped expectations. Shares opened at $7.60, with a market capitalization of approximately $143.2 million.

Squarepoint Ops LLC cut its position in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 74.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,064 shares of the company's stock after selling 132,507 shares during the period. Squarepoint Ops LLC owned about 0.24% of OptimizeRx worth $258,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Royce & Associates LP increased its stake in OptimizeRx by 0.7% in the 4th quarter. Royce & Associates LP now owns 682,030 shares of the company's stock worth $8,362,000 after buying an additional 4,700 shares in the last quarter. Rice Hall James & Associates LLC lifted its position in shares of OptimizeRx by 8.2% in the fourth quarter. Rice Hall James & Associates LLC now owns 590,674 shares of the company's stock valued at $7,242,000 after acquiring an additional 44,858 shares in the last quarter. Next Century Growth Investors LLC boosted its stake in shares of OptimizeRx by 139.8% in the fourth quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company's stock worth $6,196,000 after acquiring an additional 294,688 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of OptimizeRx by 22.3% in the first quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company's stock worth $3,540,000 after acquiring an additional 102,661 shares during the period. Finally, AWM Investment Company Inc. purchased a new stake in shares of OptimizeRx during the second quarter worth about $1,375,000. 76.47% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on OPRX. Stifel Nicolaus set a $12.00 price target on OptimizeRx in a research note on Thursday, August 13th. UBS Group set a $11.00 target price on shares of OptimizeRx in a research report on Friday, August 14th. Citizens Jmp raised their target price on shares of OptimizeRx from $9.00 to $11.00 and gave the company a "market outperform" rating in a research note on Friday, August 14th. Wall Street Zen downgraded shares of OptimizeRx from a "strong-buy" rating to a "buy" rating in a report on Monday, July 20th. Finally, Weiss Ratings upgraded shares of OptimizeRx from a "sell (d)" rating to a "sell (d+)" rating in a research note on Tuesday, August 25th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $11.43.

OptimizeRx Stock Down 0.3%

Shares of OPRX opened at $7.60 on Thursday. The stock has a market capitalization of $143.15 million, a price-to-earnings ratio of 33.04 and a beta of 1.09. OptimizeRx Corp. has a 1 year low of $4.54 and a 1 year high of $22.25. The business's 50 day simple moving average is $7.32 and its 200-day simple moving average is $6.43. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.58 and a quick ratio of 5.58.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.11 by $0.05. The firm had revenue of $20.50 million during the quarter, compared to analyst estimates of $20.20 million. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. As a group, equities analysts expect that OptimizeRx Corp. will post 0.51 earnings per share for the current fiscal year.

About OptimizeRx

OptimizeRx Corporation NASDAQ: OPRX is a digital health company that provides technology and data-driven engagement solutions for life sciences companies, healthcare providers and patients. Its platform is designed to support communication across the healthcare journey, helping pharmaceutical and biotechnology companies connect with clinicians and patients through digital channels.

The company's solutions include point-of-care messaging, patient savings and financial assistance programs, medication adherence and support services, and analytics and audience-engagement tools.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.